Bristol Myers Squibb Wins FDA Expansion for Camzyos in Pediatric Obstructive Hypertrophic Cardiomyopathy
As reported on Yahoo! News, Bristol Myers Squibb (BMS) has received an expanded approval from the US Food and Drug Administration (FDA) for Camzyos (mavacamten), extending its use to pediatric…
Continue Reading
Bristol Myers Squibb Wins FDA Expansion for Camzyos in Pediatric Obstructive Hypertrophic Cardiomyopathy
